The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAs health insurers navigate structural shifts in profitability, Evercore ISI upgraded Humana (HUM) to Outperform with a price of $367.18. The upgrade coincides with robust Q2 2026 results, where the company delivered adjusted earnings of $7.61 per share, beating estimates by 22.4%. Adjusted revenue climbed 26.2% to $40.9 billion, supported by a 20.7% surge in medical membership to 17.9 million members.
Despite top-line growth, new data reveals significant margin compression, with pre-tax profit margins dropping to 1.8% in Q2 2026 from 6.7% in 2020. Per market data, the benefit ratio climbed above 91%, highlighting the impact of rising medical costs. To counter this, management has established a strategic target to recover pre-tax margins to 3% by 2028 through improved Medicare Advantage plan quality ratings and selective market exits.
Humana's stock (HUM) closed at $388.71 on July 28, 2026, as investors weigh the long-term recovery plan against current cost headwinds. Market participants are now monitoring the execution of cost-reduction initiatives and the performance of the CenterWell segment. With full-year guidance maintained at a minimum of $9 per share, the focus remains on whether these strategic shifts can restore historical profitability levels.